Loading…
← CockpitCompetitor Analysis › 300143.SZ INKON Life Technology Co., Ltd. Class AOpen in the cockpit ↗

INKON Life Technology Co., Ltd. Class A300143.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Qingdao oncology-focused healthcare group, controlled by Haier, running cancer hospitals and making gamma-knife radiotherapy equipment.

Momentum neutral 54
Mkt cap
$985M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$6.87M
20-day average traded
Fwd P/E
50.3×
forward earnings
ROIC−WACC
+2.8 pp
WACC 8.4%
Hurdle
-2 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥6.86
1D-0.7%
1W-7.0%
1M-11.9%
3M-13.4%
6M-23.1%
YTD-9.7%
1Y-15.0%
ATR %3.4%
52w lowhigh38.0% off high

What INKON Life Technology does

Qingdao oncology-focused healthcare group, controlled by Haier, running cancer hospitals and making gamma-knife radiotherapy equipment.

Earns most of its income from running hospitals, mainly cancer-focused ones in Sichuan and Suzhou, paid by patients and insurers, with a smaller line selling Masep gamma knives and radiotherapy machines to other hospitals. Haier Group took control in 2019 and built the hospital business on top of the gamma-knife maker it inherited.

Products and services

  • Oncology and general hospitals (Sichuan, Suzhou)
  • Masep gamma knives and radiotherapy devices
  • Digital health services

Customers

  • Cancer and general-care patients and insurers
  • Hospitals buying radiotherapy equipment at home an

Where it sits in the supply chain

  • Health Care
  • Healthcare services and devices
  • Oncology hospitals and radiotherapy…

What could go right

  • Expanding oncology hospital network by build and acquisition
  • AI-linked active-health platform strategy

What could go wrong

  • Hospital pricing and reimbursement policy
  • Integration of acquired hospitals

Moat: narrow (regulatory licence, installed base). Licensed hospital network and a gamma-knife installed base; both are fragmented, local markets.

Headquarters: Qingdao, China · Founded: 1998 · Employees: 2,662

Named competitors

INKON Life Technology at a glance

Size INKON Life Technology (300143.SZ) is a China Health Care company (Medical Specialties) with a market value of $985M, the 2181st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.86 on 18 Nov 2026.

Performance Over six months the shares fell 23.1%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 22.0% over the last twelve months (peer median +10.6%); the operating margin is 11.8% (peer median 8.9%).

Valuation It trades at 50.3× forward earnings against a peer median of 19.3× (3rd most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.8 points above its cost of capital (8.4% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 92300143.SZ 81
Six months, rebased to 100: INKON Life Technology against the median of its 20 peers (local-currency closes).

INKON Life Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.06BCN¥1.88BCN¥1.56BCN¥1.47BCN¥1.16B
Revenue growth—+21%+6%+27%—
Gross profitCN¥647MCN¥476MCN¥372MCN¥389MCN¥294M
EBITDAn/aCN¥321MCN¥216MCN¥225MCN¥169M
Net incomeCN¥83.7MCN¥68.5MCN¥115MCN¥100M-CN¥596M
Free cash flowCN¥339MCN¥114MCN¥60.6MCN¥31.8MCN¥35.3M
Capital expenditureCN¥156MCN¥227MCN¥199MCN¥158MCN¥125M
Total debtCN¥805MCN¥763MCN¥336MCN¥299MCN¥115M

Quarterly statements and history in the cockpit →

INKON Life Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%CBLL30020677303046300685SFL65233010216000557780290650EUZCSTLIRMDSIBN688622KURN301101AORTIART300143.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. INKON Life Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×3002067730300685SFL6523KURNAORTIART300143.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. INKON Life Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%30020677303046300685SFL6523301021290650EUZCSTLIRMDIART300143.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. INKON Life Technology is the large dot.

INKON Life Technology competitors and peer comparison

Head to head with its named competitors (300143.SZ vs 6078.HK vs EKTA-B.ST vs ARAY)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
INKON Life Technology 300143.SZ$985M-23%+22%12%50.3×10.7%
Hygeia Healthcare 6078.HK$811M-3%+2%14%10.4×4.6%
Elekta EKTA-B.ST$2.35B0%-7%6%15.3×10.7%
Accuray ARAYn/a-81%n/an/an/an/a
Siemens Healthineers SHL.DE$53.7B+27%+1%14%18.9×9.6%

How INKON Life Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

INKON Life Technology against its 20 peers (data as of 18 Nov 2026)
Measure300143.SZPeer medianRank in peer set
1-month return-11.9%+0.9%4th lowest of 21
6-month return-23.1%-7.3%4th lowest of 21
Distance from 52-week high-38.0%-27.5%6th lowest of 21
Revenue growth (TTM)+22.0%+10.6%4th highest of 21
Operating margin11.8%8.9%8th highest of 21
Forward P/E50.3×19.3×3rd most expensive of 14
Growth the price implies (Req g, 7 yrs)10.7%6.9%5th most demanding of 14
Growth delivered (Del g)+12.9%+10.4%5th highest of 14
Hurdle (Req g minus delivered)-2.2 pp-3.0 pp7th most demanding of 14
ROIC minus cost of capital+2.8 pp+0.3 pp10th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%

Questions

Who are INKON Life Technology's main competitors?
Named competitors: Hygeia Healthcare (6078.HK), Elekta (EKTA-B.ST), Accuray (ARAY), Siemens Healthineers (SHL.DE). The cockpit's measured peer set (industry) also includes Ceribell (CBLL), Edan Instruments (300206.SZ), Mani (7730.T), JINS (3046.T), Amoy Diagnostics (300685.SZ), Safilo (SFL.MI).
Is INKON Life Technology expensive compared with its peers?
On forward p/e it trades at 50.3× against a peer median of 19.3×, 3rd most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has INKON Life Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -23.1% against -7.3% for the median peer; over one year -15.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.